

Santosh L Saraf

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6503466/santosh-l-saraf-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

147
papers

1,289
citations

19
h-index

33
g-index

153
ext. papers

1,679
ext. citations

4
avg, IF

4.47
L-index

| # | Paper | IF | Citations |
|-----|---|-----|-----------|
| 147 | Voxelotor and albuminuria in adults with sickle cell anaemia.. <i>British Journal of Haematology</i> , 2022 , | 4.5 | 0 |
| 146 | COVID-19 thromboembolism incidence, risk factors, and anticoagulation practices from a Chicago metropolitan US population.. <i>American Journal of Hematology</i> , 2022 , | 7.1 | |
| 145 | Antimicrobial resistance is a risk factor for mortality in adults with sickle cell disease. <i>Haematologica</i> , 2021 , 106, 1745-1748 | 6.6 | 1 |
| 144 | Biomarker Association with Hypertension in Mild Versus Severe Sickle Cell Disease Genotypes of a Single Center Cohort, in Comparison with African Americans from the Nhanes Study. <i>Blood</i> , 2021 , 138, 2051-2051 | 2.2 | |
| 143 | The Burden of Atrial Fibrillation in Sickle Cell Disease. <i>Blood</i> , 2021 , 138, 3119-3119 | 2.2 | |
| 142 | HIF-Mediated and Non-HIF-Mediated Differential Gene Expressions in Sickle Cell Reticulocyte and Their Impact on Clinical Manifestations. <i>Blood</i> , 2021 , 138, 950-950 | 2.2 | |
| 141 | Naloxone Use for Opioid Reversal in Patients with Sickle Cell Disease. <i>Blood</i> , 2021 , 138, 2038-2038 | 2.2 | |
| 140 | Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis. <i>Haematologica</i> , 2021 , 106, 1749-1753 | 6.6 | 2 |
| 139 | Association of Blood Pressure Genetic Risk Score with Cardiovascular Disease and CKD Progression: Findings from the CRIC Study.. <i>Kidney360</i> , 2021 , 2, 1251-1260 | 1.8 | 2 |
| 138 | Comparing the Effectiveness of Education Versus Digital Cognitive Behavioral Therapy for Adults With Sickle Cell Disease: Protocol for the Cognitive Behavioral Therapy and Real-time Pain Management Intervention for Sickle Cell via Mobile Applications (CaRISMA) Study. <i>JMIR Research Protocols</i> , 2021 , 10, e29014 | 2 | 5 |
| 137 | Evaluation of point-of-care International Normalized Ratio in sickle cell disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12533 | 5.1 | |
| 136 | Race/ethnicity and underlying disease influences hematopoietic stem/progenitor cell mobilization response: A single center experience. <i>Journal of Clinical Apheresis</i> , 2021 , 36, 634-644 | 3.2 | 2 |
| 135 | The vasculopathic cord between pre-eclampsia and kidney function in sickle cell disease. <i>British Journal of Haematology</i> , 2021 , 194, 947-949 | 4.5 | |
| 134 | Biomarkers of clinical severity in treated and untreated sickle cell disease: a comparison by genotypes of a single center cohort and African Americans in the NHANES study. <i>British Journal of Haematology</i> , 2021 , 194, 767-778 | 4.5 | 1 |
| 133 | Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease. <i>Kidney International</i> , 2021 , 100, 1292-1302 | 9.9 | 1 |
| 132 | Engulfment and cell motility 1 (ELMO1) and apolipoprotein A1 (APOA1) as candidate genes for sickle cell nephropathy. <i>British Journal of Haematology</i> , 2021 , 193, 628-632 | 4.5 | 3 |
| 131 | Urinary Kringle Domain-Containing Protein HGFL: A Validated Biomarker of Early Sickle Cell Anemia-Associated Kidney Disease. <i>American Journal of Nephrology</i> , 2021 , 52, 582-587 | 4.6 | 0 |

| | | | |
|-----|---|-----|---|
| 130 | Using machine learning to predict rapid decline of kidney function in sickle cell anemia. <i>EJHaem</i> , 2021 , 2, 257-260 | 0.9 | |
| 129 | Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres. <i>British Journal of Haematology</i> , 2021 , 192, 761-768 | 4.5 | 9 |
| 128 | Effects of Renin-Angiotensin Blockade and on Kidney Function in Sickle Cell Disease. <i>EJHaem</i> , 2021 , 2, 483-484 | 0.9 | 1 |
| 127 | Thrombomodulin and multiorgan failure in sickle cell anemia.. <i>American Journal of Hematology</i> , 2021 , | 7.1 | |
| 126 | Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease. <i>Blood Advances</i> , 2020 , 4, 1978-1986 | 7.8 | 8 |
| 125 | Anemia and Incident End-Stage Kidney Disease. <i>Kidney360</i> , 2020 , 1, 623-630 | 1.8 | 4 |
| 124 | Potential Contribution of Pulmonary Thromboembolic Disease in Pulmonary Hypertension in Sickle Cell Disease. <i>Annals of the American Thoracic Society</i> , 2020 , 17, 899-901 | 4.7 | 2 |
| 123 | Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease. <i>PLoS ONE</i> , 2020 , 15, e0229710 | 3.7 | 5 |
| 122 | Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease. <i>Pharmacotherapy</i> , 2020 , 40, 525-534 | 5.8 | 5 |
| 121 | Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease. <i>Pharmacotherapy</i> , 2020 , 40, 535-543 | 5.8 | 8 |
| 120 | Heme A1M@d at the kidney in sickle cell disease. <i>Blood</i> , 2020 , 135, 979-981 | 2.2 | 2 |
| 119 | Cancer Incidence and Chemotherapy Tolerance in Patients with Sickle Cell Disease. <i>Blood</i> , 2020 , 136, 24-25 | 2.2 | |
| 118 | Effects of Hydroxyurea and Renin-Angiotensin Blockade on Kidney Function in Sickle Cell Disease. <i>Blood</i> , 2020 , 136, 21-22 | 2.2 | |
| 117 | Mass-Spectrometry Analysis of Urinary Biomarkers of Endothelial Injury in Sickle Cell Anemia Patients. <i>Blood</i> , 2020 , 136, 28-29 | 2.2 | |
| 116 | The Effect of Crizanlizumab on the Number of Days Requiring Opioid Use for Management of Pain Associated with Vaso-Occlusive Crises in Patients with Sickle Cell Disease: Results from the Sustain Trial. <i>Blood</i> , 2020 , 136, 32-33 | 2.2 | 1 |
| 115 | Use of Multiple Urinary Biomarkers for Early Detection of Chronic Kidney Disease in Sickle Cell Anemia Patients. <i>Blood</i> , 2020 , 136, 30-30 | 2.2 | 0 |
| 114 | Lower Apache II Score and Exchange Transfusions Predict Better Outcomes in the Intensive Care Unit for Patients with Sickle Cell Disease. <i>Blood</i> , 2020 , 136, 18-19 | 2.2 | |
| 113 | Correction of Point-of-Care International Normalized Ratio (INR) Values in Patients with Sickle Cell Disease. <i>Blood</i> , 2020 , 136, 34-35 | 2.2 | |

| | | | |
|-----|---|-----|----|
| 112 | FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease. <i>Blood</i> , 2020 , 136, 19-20 | 2.2 | 8 |
| 111 | S100B has pleiotropic effects on vaso-occlusive manifestations in sickle cell disease. <i>American Journal of Hematology</i> , 2020 , 95, E62-E65 | 7.1 | 1 |
| 110 | Chronic opioid use can be reduced or discontinued after haematopoietic stem cell transplantation for sickle cell disease. <i>British Journal of Haematology</i> , 2020 , 191, e70-e72 | 4.5 | 1 |
| 109 | Metabolomic Markers of Kidney Function Decline in Patients With Diabetes: Evidence From the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2020 , 76, 511-520 | 7.4 | 14 |
| 108 | COVID-19 infection in patients with sickle cell disease. <i>British Journal of Haematology</i> , 2020 , 189, 851-852 | 5 | 66 |
| 107 | Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study. <i>Blood Advances</i> , 2020 , 4, 1501-1511 | 7.8 | 10 |
| 106 | Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease 2020 , 15, e0229710 | | |
| 105 | Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease 2020 , 15, e0229710 | | |
| 104 | Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease 2020 , 15, e0229710 | | |
| 103 | Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease 2020 , 15, e0229710 | | |
| 102 | "Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia. <i>American Journal of Hematology</i> , 2019 , 94, E112-E115 | 7.1 | 5 |
| 101 | Laparoscopic Sleeve Gastrectomy in Sickle Cell Disease: a Case Series. <i>Obesity Surgery</i> , 2019 , 29, 3762-3764 | 5.4 | 4 |
| 100 | Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population-based cohort analysis. <i>British Journal of Haematology</i> , 2019 , 185, 116-127 | 4.5 | 9 |
| 99 | Kidney ultrasound findings according to kidney function in sickle cell anemia. <i>American Journal of Hematology</i> , 2019 , 94, E288-E291 | 7.1 | 3 |
| 98 | The experience of adults with sickle cell disease and their HLA-matched adult sibling donors after allogeneic hematopoietic stem cell transplantation. <i>Journal of Advanced Nursing</i> , 2019 , 75, 2943-2951 | 3.1 | 4 |
| 97 | Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Sickle Cell Disease. <i>Journal of Clinical Medicine</i> , 2019 , 8, | 5.1 | 3 |
| 96 | Type 2 diabetes in adults with sickle cell disease: can we dive deeper? Response to Skinner et al. <i>British Journal of Haematology</i> , 2019 , 186, 782-783 | 4.5 | |
| 95 | Thrombomodulin and Endothelial Dysfunction in Sickle Cell Anemia. <i>Blood</i> , 2019 , 134, 3558-3558 | 2.2 | 1 |

| | | | |
|----|--|-----|----|
| 94 | Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects. <i>Blood</i> , 2019 , 134, 616-616 | 2.2 | 3 |
| 93 | Progression of Albuminuria in Sickle Cell Anemia: A Multicenter, Longitudinal Study. <i>Blood</i> , 2019 , 134, 1004-1004 | 2.2 | |
| 92 | Biomarkers of Cardiopulmonary, Renal, and Liver Dysfunction in an Adult Sickle Cell Disease Cohort. <i>Blood</i> , 2019 , 134, 3574-3574 | 2.2 | 1 |
| 91 | Risk Factors for Kidney Disease in Hb SC and Hb S β -Thalassemia Sickle Cell Disease. <i>Blood</i> , 2019 , 134, 2299-2299 | 2.2 | |
| 90 | Manifestations of Reduced Kidney Function Occur at a Higher Estimated Glomerular Filtration Rate in Sickle Cell Anemia. <i>Blood</i> , 2019 , 134, 2268-2268 | 2.2 | 0 |
| 89 | Impact of Intravenous Opioid Shortage on Managing Pain Crisis in Sickle Cell Disease. <i>Blood</i> , 2019 , 134, 3390-3390 | 2.2 | |
| 88 | The morbidity and mortality of end stage renal disease in sickle cell disease. <i>American Journal of Hematology</i> , 2019 , 94, E138-E141 | 7.1 | 4 |
| 87 | Use of metformin in patients with sickle cell disease. <i>American Journal of Hematology</i> , 2019 , 94, E13-E15 | 7.1 | 2 |
| 86 | High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease. <i>American Journal of Hematology</i> , 2019 , 94, E5-E7 | 7.1 | 1 |
| 85 | Health-Related Quality of Life and Personal Life Goals of Adults With Sickle Cell Disease After Hematopoietic Stem Cell Transplantation. <i>Western Journal of Nursing Research</i> , 2019 , 41, 555-575 | 2 | 5 |
| 84 | Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1759-1765 | 4.7 | 35 |
| 83 | Progressive glomerular and tubular damage in sickle cell trait and sickle cell anemia mouse models. <i>Translational Research</i> , 2018 , 197, 1-11 | 11 | 8 |
| 82 | A prospective study of intravenous pentamidine for PJP prophylaxis in adult patients undergoing intensive chemotherapy or hematopoietic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2018 , 53, 300-306 | 4.4 | 7 |
| 81 | Urinary orosomucoid is associated with progressive chronic kidney disease stage in patients with sickle cell anemia. <i>American Journal of Hematology</i> , 2018 , 93, E107-E109 | 7.1 | 9 |
| 80 | Red blood cell alloimmunization in sickle cell disease: assessment of transfusion protocols during two time periods. <i>Transfusion</i> , 2018 , 58, 1588-1596 | 2.9 | 8 |
| 79 | Hemolysis and hemolysis-related complications in females vs. males with sickle cell disease. <i>American Journal of Hematology</i> , 2018 , 93, E376-E380 | 7.1 | 11 |
| 78 | Health Care Utilization in Transplanted Versus Non-Transplanted Sickle Cell Disease Patients. <i>Blood</i> , 2018 , 132, 313-313 | 2.2 | 1 |
| 77 | Regulatory Genetic Variation at the S100B Gene Associates with Vaso-Occlusive Manifestations in Sickle Cell Disease. <i>Blood</i> , 2018 , 132, 1063-1063 | 2.2 | 1 |

| | | | |
|----|---|-----|----|
| 76 | Type 2 Diabetes Mellitus in Patients with Sickle Cell Disease: A Population-Based Longitudinal Analysis of Three Cohorts. <i>Blood</i> , 2018 , 132, 4817-4817 | 2.2 | 1 |
| 75 | Pulmonary Function Abnormalities in Adults with Sickle Cell Anemia. <i>Blood</i> , 2018 , 132, 3664-3664 | 2.2 | |
| 74 | Role of Automated Red Cell Exchange in Acute and Chronic Complications of Sickle Cell Disease. <i>Blood</i> , 2018 , 132, 3674-3674 | 2.2 | |
| 73 | Clinical, Laboratory, and Genetic Risk Factors for Thrombosis in Sickle Cell Disease. <i>Blood</i> , 2018 , 132, 9-9 | 2.2 | |
| 72 | Cancer Incidence in Sickle Cell Disease:an Institutional Experience. <i>Blood</i> , 2018 , 132, 1087-1087 | 2.2 | |
| 71 | Kidney Ultrasound Findings in Sickle Cell Anemia According to Kidney Disease and the APOL1 G1/G2 Risk Variants. <i>Blood</i> , 2018 , 132, 3663-3663 | 2.2 | |
| 70 | Association of Inpatient Opioid Utilization and Readmission Risk in Sickle Cell Disease. <i>Blood</i> , 2018 , 132, 4699-4699 | 2.2 | |
| 69 | Maximum Tolerated Dose Versus Fixed Low-Dose Hydroxyurea for Treatment of Adults with Sickle Cell Anemia - Retrospective Comparison of Two Studies. <i>Blood</i> , 2018 , 132, 3656-3656 | 2.2 | |
| 68 | A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients. <i>Blood</i> , 2018 , 132, 5218-5218 | 2.2 | |
| 67 | Program expansion of a day hospital dedicated to manage sickle cell pain. <i>American Journal of Hematology</i> , 2018 , 93, E20-E21 | 7.1 | 5 |
| 66 | Identification of ceruloplasmin as a biomarker of chronic kidney disease in urine of sickle cell disease patients by proteomic analysis. <i>American Journal of Hematology</i> , 2018 , 93, E45-E47 | 7.1 | 10 |
| 65 | Erythropoiesis-stimulating agents in sickle cell anaemia. <i>British Journal of Haematology</i> , 2018 , 182, 602-605 | 4.5 | 5 |
| 64 | Characterization of opioid use in sickle cell disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 479-486 | 2.6 | 25 |
| 63 | and acute kidney injury in sickle cell anemia. <i>Blood</i> , 2018 , 132, 1621-1625 | 2.2 | 11 |
| 62 | Risk factors for vitamin D deficiency in sickle cell disease. <i>British Journal of Haematology</i> , 2018 , 181, 828-835 | 4.5 | 11 |
| 61 | Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study. <i>British Journal of Haematology</i> , 2018 , 182, 259-270 | 4.5 | 12 |
| 60 | Fixed Low-Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Anemia in Nigeria. <i>American Journal of Hematology</i> , 2018 , 93, E193 | 7.1 | 7 |
| 59 | Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease. <i>Seminars in Hematology</i> , 2018 , 55, 87-93 | 4 | 34 |

| | | | |
|----|---|-----|----|
| 58 | Reply to Ruan X et al: "A comment on pattern of opioid use in sickle cell disease". <i>American Journal of Hematology</i> , 2017 , 92, E43 | 7.1 | 1 |
| 57 | Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial. <i>American Journal of Hematology</i> , 2017 , 92, E520-E528 | 7.1 | 23 |
| 56 | Association of circulating transcriptomic profiles with mortality in sickle cell disease. <i>Blood</i> , 2017 , 129, 3009-3016 | 2.2 | 14 |
| 55 | APOL1, β -thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia. <i>Haematologica</i> , 2017 , 102, e1-e6 | 6.6 | 28 |
| 54 | Use of anti-inflammatory analgesics in sickle-cell disease. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017 , 42, 656-660 | 2.2 | 7 |
| 53 | Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways. <i>Haematologica</i> , 2017 , 102, e282-e284 | 6.6 | 1 |
| 52 | Associations of β -thalassemia and BCL11A with stroke in Nigerian, United States, and United Kingdom sickle cell anemia cohorts. <i>Blood Advances</i> , 2017 , 1, 693-698 | 7.8 | 8 |
| 51 | Low Fixed Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Disease in Nigeria. <i>Blood</i> , 2017 , 130, 981-981 | 2.2 | 3 |
| 50 | Quantitative Proteomics Identify Urinary Hgfl Protein As a Potential Marker for the Development of Chronic Kidney Disease in Sickle Cell Disease Patients. <i>Blood</i> , 2017 , 130, 967-967 | 2.2 | |
| 49 | A genetic variation associated with plasma erythropoietin and a non-coding transcript of PRKAR1A in sickle cell disease. <i>Human Molecular Genetics</i> , 2016 , 25, 4601-4609 | 5.6 | 3 |
| 48 | Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center. <i>Pharmacotherapy</i> , 2016 , 36, 1166-1172 | 5.8 | 6 |
| 47 | Safety of chronic transdermal fentanyl use in patients receiving hemodialysis. <i>American Journal of Health-System Pharmacy</i> , 2016 , 73, 947-8 | 2.2 | 6 |
| 46 | Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 441-8 | 4.7 | 84 |
| 45 | Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016 , 11, 207-15 | 6.9 | 54 |
| 44 | Phase 1 Evaluation of Oral Tetrahydrouridine-Decitabine As Non-Cytotoxic Epigenetic Disease Modification for Sickle Cell Disease. <i>Blood</i> , 2016 , 128, 124-124 | 2.2 | 2 |
| 43 | Hydroxyurea for Treatment of Sickle Cell Disease in Adults in Africa. <i>Blood</i> , 2016 , 128, 1305-1305 | 2.2 | 1 |
| 42 | Urinary Ceruloplasmin Concentration Predicts Development of Kidney Disease in Sickle Cell Disease Patients. <i>Blood</i> , 2016 , 128, 4865-4865 | 2.2 | 1 |
| 41 | Allogeneic Hematopoietic Cell Transplant in Sickle Cell Disease 2016 , 89-96 | | |

| | | | |
|----|--|-----|----|
| 40 | Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Kidney Function in Patients with Sickle Cell Disease. <i>Blood</i> , 2016 , 128, 3666-3666 | 2.2 | |
| 39 | Elevated Levels of Hgfl Protein in Sickle Cell Disease Urine Samples That Induce Glomerular Permeability. <i>Blood</i> , 2016 , 128, 4841-4841 | 2.2 | |
| 38 | Genetic Modifiers Identify a High Risk Group for Stroke in Three Independent Cohorts of Sickle Cell Anemia Patients. <i>Blood</i> , 2016 , 128, 1015-1015 | 2.2 | |
| 37 | A Multi-Center, Phase-2 Trial of Losartan for the Nephropathy of Sickle Cell Anemia. <i>Blood</i> , 2016 , 128, 265-265 | 2.2 | 1 |
| 36 | Progressive Glomerular Damage in Sickle Cell Trait and Sickle Cell Anemia Mouse Models. <i>Blood</i> , 2016 , 128, 3637-3637 | 2.2 | |
| 35 | Utility of the revised cardiac risk index for predicting postsurgical morbidity in Hb SC and Hb S β -thalassemia sickle cell disease. <i>American Journal of Hematology</i> , 2016 , 91, E316-7 | 7.1 | 1 |
| 34 | Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 350-7 | 2 | 10 |
| 33 | Patterns of opioid use in sickle cell disease. <i>American Journal of Hematology</i> , 2016 , 91, 1102-1106 | 7.1 | 18 |
| 32 | Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers. <i>Transfusion</i> , 2015 , 55, 864-74 | 2.9 | 13 |
| 31 | Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy. <i>Haematologica</i> , 2015 , 100, 1275-84 | 6.6 | 44 |
| 30 | Genetic polymorphism of APOB is associated with diabetes mellitus in sickle cell disease. <i>Human Genetics</i> , 2015 , 134, 895-904 | 6.3 | 14 |
| 29 | Changes in Conjunctival Hemodynamics Predict Albuminuria in Sickle Cell Nephropathy. <i>American Journal of Nephrology</i> , 2015 , 41, 487-93 | 4.6 | 11 |
| 28 | Chronic Opioid Use Pattern in Adult Patients with Sickle Cell Disease. <i>Blood</i> , 2015 , 126, 3400-3400 | 2.2 | 3 |
| 27 | Utility of the Revised Cardiac Index Score for Predicting Post-Surgical Outcome in Hb SC or S β -Thalassemia Sickle Cell Disease. <i>Blood</i> , 2015 , 126, 3413-3413 | 2.2 | |
| 26 | Assessment of Bone Marrow Function in Sickle Cell Anaemia Patients Using Corrected Reticulocyte Counts. <i>Blood</i> , 2015 , 126, 4581-4581 | 2.2 | |
| 25 | CCN2 - Exploring a New Biomarker in Myelofibrosis. <i>Blood</i> , 2015 , 126, 4063-4063 | 2.2 | |
| 24 | Conjunctival microvascular hemodynamics following vaso-occlusive crisis in sickle cell disease. <i>Clinical Hemorheology and Microcirculation</i> , 2015 , 62, 359-67 | 2.5 | 6 |
| 23 | Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia. <i>British Journal of Haematology</i> , 2014 , 164, 729-39 | 4.5 | 75 |

| | | | |
|----|---|------|-----|
| 22 | Differences in the clinical and genotypic presentation of sickle cell disease around the world. <i>Paediatric Respiratory Reviews</i> , 2014 , 15, 4-12 | 4.8 | 59 |
| 21 | Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 2034-41 | 4.7 | 26 |
| 20 | Comparison of patients from Nigeria and the USA highlights modifiable risk factors for sickle cell anemia complications. <i>Hemoglobin</i> , 2014 , 38, 236-43 | 0.6 | 21 |
| 19 | ARTS: automated randomization of multiple traits for study design. <i>Bioinformatics</i> , 2014 , 30, 1637-9 | 7.2 | 2 |
| 18 | Hyperfiltration is associated with the development of microalbuminuria in patients with sickle cell anemia. <i>American Journal of Hematology</i> , 2014 , 89, 1156-7 | 7.1 | 27 |
| 17 | Hypoxic response contributes to altered gene expression and precapillary pulmonary hypertension in patients with sickle cell disease. <i>Circulation</i> , 2014 , 129, 1650-8 | 16.7 | 27 |
| 16 | LINAC-based intensity modulated total marrow irradiation (TMI) in addition to myeloablative fludarabine/IV busulfan conditioning prior to allogeneic stem cell transplant for high-risk hematologic malignancies: A phase I study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7045-7045 | 2.2 | |
| 15 | Feasibility of implementing a comprehensive warfarin pharmacogenetics service. <i>Pharmacotherapy</i> , 2013 , 33, 1156-64 | 5.8 | 57 |
| 14 | Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1989-95 | 1.9 | 53 |
| 13 | Hemoglobinuria Is a Risk Factor For Kidney Disease Progression In Sickle Cell Anemia. <i>Blood</i> , 2013 , 122, 996-996 | 2.2 | |
| 12 | Myeloablative Fludarabine/ IV Busulfan Combined With Linac Based Intensity Modulated Total Marrow Irradiation (IM-TMI) In Allogeneic Stem Cell Transplant For High Risk Hematologic Malignancies: A Phase I Study. <i>Blood</i> , 2013 , 122, 3285-3285 | 2.2 | |
| 11 | Role of Ethnicity in Clinical Outcomes of Patients with Ph-Negative Myeloproliferative Neoplasms. <i>Blood</i> , 2012 , 120, 2076-2076 | 2.2 | 1 |
| 10 | Conjunctival Biopsy to Guide Treatment of Chronic Ocular Gvhd. <i>Blood</i> , 2012 , 120, 4491-4491 | 2.2 | |
| 9 | Clinical and Laboratory Predictors for Renal Damage in Sickle Cell Disease. <i>Blood</i> , 2012 , 120, 3252-3252 | 2.2 | |
| 8 | Standard clinical practice underestimates the role and significance of erythropoietin deficiency in sickle cell disease. <i>British Journal of Haematology</i> , 2011 , 153, 386-92 | 4.5 | 7 |
| 7 | Update on meningiomas. <i>Oncologist</i> , 2011 , 16, 1604-13 | 5.7 | 109 |
| 6 | Favorable Responses to Novel Agents for Multiple Myeloma in African American Patients,. <i>Blood</i> , 2011 , 118, 4213-4213 | 2.2 | |
| 5 | Non-p53 Dependent, Leukemia Initiating-Cell Selective, Therapy.. <i>Blood</i> , 2009 , 114, 2077-2077 | 2.2 | 1 |

| | | | |
|---|---|-----|----|
| 4 | Clinical effectiveness of decitabine in severe sickle cell disease. <i>British Journal of Haematology</i> , 2008 , 141, 126-9 | 4.5 | 56 |
| 3 | Significance of, and Difficulty in Diagnosing, Erythropoietin Deficiency in Sickle Cell Anemia. <i>Blood</i> , 2008 , 112, 2479-2479 | 2.2 | |
| 2 | African American Patients with Multiple Myeloma Have Prolonged Responses after Autologous Stem Cell Transplantation.. <i>Blood</i> , 2005 , 106, 3131-3131 | 2.2 | |
| 1 | Hyperkalemia and Metabolic Acidosis Occur at Higher Estimated Glomerular Filtration Rates in Sickle Cell Disease. <i>Kidney360</i> ,10.34067/KID.0006802021 | 1.8 | 0 |